Haemostatic and rheological factors as predictors of restenosis following percutaneous transluminal angioplasty.
OBJECTIVE
To determine whether pre-angioplasty levels of haemostatic and rheological factors predicted restenosis of the dilated arterial segment following percutaneous transluminal angioplasty.


METHODS
Prospective study, Two regional hospital centres for angioplasty in Edinburgh and Glasgow, Scotland, UK.


METHODS
Haemostatic and rheological factors were measured in 102 subjects with atherosclerotic disease of the lower limbs, immediately prior to percutaneous transluminal angioplasty. Subjects were followed up after 2-3 years for restenosis of the original angioplasty site using duplex scanning.


RESULTS
Baseline clinical characteristics were similar between subjects who restenosed (n = 27) and those with no restenosis (n = 39), except that occluded lesions were more likely to restenose than stenoses (p < or = 0.05). There was no significant difference in age- and sex-adjusted mean levels of whole blood viscosity, plasma viscosity, haematocrit, von Willebrand factor, fibrin D-dimer or plasminogen activator inhibitor-1 activity between the stenosed and no restenosis groups (p > 0.1), but mean plasma fibrinogen was lower in the restenosed group (3.31 g/l vs. 3.75 g/l; p < or = 0.05). These results persisted after multivariate adjustment for smoking habit and type of lesion dilated.


CONCLUSIONS
This study provides no evidence that raised, pre-angioplasty levels of haemostatic and rheological factors predict restenosis following percutaneous transluminal angioplasty of the arteries of the lower limbs.
Price
J F
JF
Wolfson Unit for the Prevention of Peripheral Vascular Diseases, Department of Public Health Sciences, University of Edinburgh, U.K.
Mamode
N
N
Smith
F B
FB
Woodburn
K R
KR
Rumley
A
A
Lowe
G D
GD
Fowkes
F G
FG
D000800:Angioplasty, Balloon; D001161:Arteriosclerosis / Q000097:blood* / Q000628:therapy; D001809:Blood Viscosity; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006400:Hematocrit; D018056:Hemorheology; D006487:Hemostasis; D006801:Humans; D007866:Leg / Q000098:blood supply*; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis; D011446:Prospective Studies; D012008:Recurrence; D014841:von Willebrand Factor / Q000032:analysis
D005338:Fibrin Fibrinogen Degradation Products; D017395:Plasminogen Activator Inhibitor 1; C036309:fibrin fragment D; D014841:von Willebrand Factor; D005340:Fibrinogen